Cargando…

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

BACKGROUND: PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer. METHODS: Patients who had metastatic pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, A H, Tempero, M A, Shan, Y-S, Su, W-C, Lin, Y-L, Dito, E, Ong, A, Wang, Y-W, Yeh, C G, Chen, L-T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749576/ https://www.ncbi.nlm.nih.gov/pubmed/23880820 http://dx.doi.org/10.1038/bjc.2013.408

Ejemplares similares

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
por: Chang, T. C., et al.
Publicado: (2015)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
por: Takada, Ryoji, et al.
Publicado: (2023)

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
por: Glassman, Danielle C., et al.
Publicado: (2018)

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
por: Chiang, Nai-Jung, et al.
Publicado: (2016)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
por: Ko, Andrew H
Publicado: (2016)

Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers
por: Allo, Gabriel, et al.
Publicado: (2022)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
por: Miki, Masami, et al.
Publicado: (2022)

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ioka, T, et al.
Publicado: (2017)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
por: Kawakami, Takeshi, et al.
Publicado: (2023)

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
por: Liang, Barry J., et al.
Publicado: (2020)

A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer
por: Ikoma, Tatsuki, et al.
Publicado: (2023)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
por: Procaccio, Letizia, et al.
Publicado: (2023)

Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer
por: Patel, Akanksha, et al.
Publicado: (2022)

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis
por: Want, Muzamil Y, et al.
Publicado: (2017)

Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity
por: Zheng, Jinzi, et al.
Publicado: (2015)

Transverse instability excited by r.f. deflecting modes for PEP
por: Chao, A W, et al.
Publicado: (1979)

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
por: Ulrich-Pur, H, et al.
Publicado: (2003)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
por: Möhring, Christian, et al.
Publicado: (2023)

Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
por: Nagata, Keiji, et al.
Publicado: (2022)

FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
por: Kobayashi, Satoshi, et al.
Publicado: (2023)

Pep for PEP-II
Publicado: (1995)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
por: Yamai, Takuo, et al.
Publicado: (2022)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

A “Trojan Horse” Strategy: The Preparation of Bile Acid-Modifying Irinotecan Hydrochloride Nanoliposomes for Liver-Targeted Anticancer Drug Delivery System Study
por: Zhou, Tao, et al.
Publicado: (2023)

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
por: Stathopoulos, G P, et al.
Publicado: (2006)

Application of Model-Independent Analysis to PEP-II Rings
por: Cai, Y, et al.
Publicado: (2001)

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
por: Harada, Kazuaki, et al.
Publicado: (2023)

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
por: Georgoulias, V, et al.
Publicado: (2004)

Performance of HQ02, an optimized version of the 120 mm $Nb_3Sn$ LARP quadrupole
por: Chlachidze, G, et al.
Publicado: (2014)

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Park, Se Jun, et al.
Publicado: (2021)

Beam Commissioning of the PEP-II High Energy Ring
por: Wienands, U, et al.
Publicado: (1999)

Swamp plots for dynamic aperture studies of PEP-II lattices
por: Yan, Y T, et al.
Publicado: (1996)

Preparation of Benzothiazolyl-Decorated Nanoliposomes
por: Mourtas, Spyridon, et al.
Publicado: (2019)

Folate-Targeted Nanoliposomal Chemophototherapy
por: Chitgupi, Upendra, et al.
Publicado: (2023)

The application of Lie algebras methods to PEP-II design
por: Irwin, J, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_puehgc3ngt9if37mfuu9n6s3h5